Sanofi: to hold a virtual R&D day

(CercleFinance.com) - On Tuesday Sanofi announced that it will hold a virtual day dedicated to research and development (R&D) for the investment community, the fourth of a five-part series highlighting how Sanofi is leading with innovation.


The event will "highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients".

Regarding the accelerated development of a COVID-19 recombinant protein-based vaccine, Sanofi expects a Phase 1/2 study to start in September and at the earliest, full approval by the first half of 2021.


Copyright (c) 2020 CercleFinance.com. All rights reserved.